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Objective: Osteoarthritis (OA) epidemiologic data are scarce in Europe. To estimate the prevalence of
symptomatic knee and hip OA in a multiregional sample in France.
Design: A two-phase population-based survey was conducted in six regions in 2007e2009. On initial phone
contact using random-digit dialing, subjects 40e75 years old were screened with a validated questionnaire.
Subjects screened positive were invited for ascertainment: physical examination and hip and/or knee radi-
ography (KellgreneLawrence grade 2). Multiple imputation for data missing not-at-random was used to
account for refusals.
Results: Of 63,232 homes contacted, 27,632 were eligible, 9621 subjects screened positive, 3707 partici-
pated fully in the ascertainment phase, and 1010 had symptomatic OA: 317 hip, 756 knee. Hip OA preva-
lence according to age class ranged from 0.9% to 3.9% for men and 0.7e5.1% for women. Knee OA ranged
from 2.1% to 10.1% for men and 1.6e14.9% for women. Both differed by geographical region. The hip and
knee standardized prevalence was 1.9% and 4.7% for men and 2.5% and 6.6% for women, respectively.
Conclusions: This conﬁrmed the feasibility of using a screening questionnaire for eliciting population-based
estimates of OA. In France, it increases with age and is greater among women above the age of 50. The
geographical disparity of hip and knee OA parallels the distribution of obesity.
Study registration ID number 906297 at http://www.clinicaltrials.gov/.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.e 10th ACR/ARHP American
SA, on November 10th, 2010.
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Osteoarthritis (OA) is a major cause of disability in elderly
people, the main source of hip and knee arthroplasty and therefore
a major public health problem. Although known as a frequent
disease increasingwith age, the population-based prevalence of hip
and knee OA has seldom been reported, especially in Europe.ublished by Elsevier Ltd. All rights reserved.
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reported1, but discrepant estimates of prevalence mainly result
from variable deﬁnitions of hip and knee OA. The deﬁnitions are of
three categories: radiological OA, clinical OA, and both, for symp-
tomatic OA conﬁrmed on radiographs. The deﬁnition combining
radiological and clinical features is the most important in public
health because it reﬂects the real burden of disease, need for care
and access to health care providers.
Only a few studies of OA prevalence have been conducted in
large general-population samples2. These include the Framingham
OA study3, the NHANES survey III4, the Johnston County OA
project5,6, the Zoetermeer survey7 and the Quintana study in
Spain8. Two of these studies are more than 15 years old. Most of the
other studies were of limited sample size. Overall, prevalence
estimates ranged from 6% to 17% and 2e10% for knee and hip OA,
respectively, which indicates that OA is the most frequent muscu-
loskeletal disease. Data from studies conducted in Europe indicate
some geographical disparity (Appendix 1).
Estimating prevalence of OA in a population requires directly
examining clinical and radiographic data in a large population
sample, with therefore a large proportion of unjustiﬁed radiography
results. Although some studies have attempted to collect cases with
such a direct approach, they did not use radiography for ascertain-
ment. Indeed, conducting radiography in a large population can be
unrealistic and unethical. Therefore, a two-phase survey is neces-
sary: a screening phase that identiﬁes putative cases, and a clinical
and radiography examination phase to conﬁrm OA cases. In
a preliminary work we have developed a telephone-administered
questionnaire for screening OA in the general population, assessed
its validity (sensitivity and speciﬁcity) in a caseecontrol study9 and
tested the feasibility of this two-phase strategy10.
Here, we report on a two-phase, population-based survey of
subjects aged 40e75 years in amultiregional representative sample
in France to estimate the prevalence of symptomatic radiologically
conﬁrmed knee and hip OA.
Method
A two-phase survey with population-screening and
case-ascertainment phases was conducted in Brittany (West),
Côte d’Azur (South-East), Lorraine (East), Picardie (North), Paris
(North-Centre) and Toulouse (South-West) areas representing
a widespread coverage of the population in France and allowing for
study of geographical distribution. Each area was selected to cover
households within 1-h by public or private transportation to the
university hospital investigating centre. The survey was conducted
from April 2007 to October 2009.
Screening phase
The ﬁrst phase of sampling conducted by telephone involved
use of a random selection of telephone numbers in each selected
area. Interviewers systematically asked whether phone numbers
were of enterprises, businesses, seniors’ residences or second
homes, and therefore excluded.
We randomly selected one adult in each household by using the
next birthday method11. The person ﬁrst answering the phone was
asked to name the household residents who were between 40 and
75 years old. The person with a birthday closest to the interview
date was then invited to answer the screening questionnaire.
Except for age, no exclusion criteria were applied.
The screening questionnaire comprises four items about the hip
and four about the knee and was developed from a literature
review and the American College of Rheumatology (ACR) criteria
for OA12,13 (Appendix 2). It asks about typical symptoms of knee orhip OA during the previous 4 weeks and includes one question
about self-reported OA diagnosis. The questionnaire as a whole has
a sensitivity of 96% and a speciﬁcity of 90%9. Subjects who screened
positive for presence of OA (presence of at least one of the listed
characteristic symptoms and/or self-reporting OA diagnosis, i.e.,
any positive answer to one among the four items) were invited to
participate in the ascertainment phase in the investigation centre.
Ascertainment phase
The case-ascertainment phase was conducted by physicians
trained in rheumatology. Subjects underwent clinical examination
and knee and/or hip radiography. Data for both clinical diagnosis
(i.e., physician judgment) and ACR criteria for hip and knee OAwere
collected on standard forms.
Subjects who gave positive answers for one or more items about
the knee on the screening questionnaire underwent radiography to
obtain weight-bearing anteroposterior (AP), posteroanterior semi-
ﬂexed and axial/sky views of the knee. Subjects who gave positive
answers for one or more hip items underwent radiography to
obtain AP pelvis and oblique (Lequesne) views of the hip. Radiog-
raphy was not performed in those who had one of correct quality in
the past 12 months. All radiographs were read centrally by two
readers (BM, EV) who were blinded to clinical condition and
questionnaire results. Single reading of radiographs was prepared
by training both readers on a pilot study sample (N¼ 1380)10.
Target hip and knee femoro-tibial compartments were scored by
the KellgreneLawrence (KeL) method14 on the basis of the degree
of osteophyte formation, joint space narrowing, sclerosis, and joint
deformity distinguished in ﬁve grades (0: no OA, 1: doubtful, 2:
minimal, 3: moderate, 4: severe). Cases were deﬁned as symp-
tomatic OA according to the physician (clinical) and OA with
KeL 2 on radiography for the same joint.
The study protocol was approved by institutional review boards
(Comité Consultatif sur le Traitement de l’Information en matière de
Recherche dans le domaine de la Santé, and Comité National Infor-
matique et Liberté).
Statistical analysis
Prevalence of OA was estimated for each sex, age class (40e49,
50e59, 60e69, 70e75 years) and geographic area. To account for
nonparticipants at various steps of the screening and ascertainment
processes, amultistep statistical procedurewasdeveloped to control
for non-response bias by the multiple imputation technique15.
We found screening refusers (refusals before responding the
screening questionnaire), early ascertainment refusers (refusals to
enter the ascertainment phase despite a positive answer on the
screening questionnaire), subjects who were secondarily unreach-
able (not reached on the phone for the ascertainment phase), late
ascertainment refusers (refusals to schedule an ascertainment visit)
and withdrawers (subjects who did not show up at the scheduled
visit) (Fig.1). Completerswere subjects screenednegative forOAand
subjects who completed the whole ascertainment phase.
Differences between participants and nonparticipants were
examined by multinomial logistic regression, with the different
types of nonparticipation treated as dependent variables. Tested
variables were age, sex, socio-professional category in eight
classes according to national statistics institute (INSEE),
geographic area and the eight items of the screening question-
naire, data that were available for all subjects except screening
refusers, for whom data were limited to age, sex and geographic
location. The same variables were tested in multivariate logistic
regression to determine factors predicting symptomatic hip and/
or knee OA in participants at the 0.05 signiﬁcance level. Final
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Fig. 1. Flow-chart of the study.
F. Guillemin et al. / Osteoarthritis and Cartilage 19 (2011) 1314e13221316regression models were constructed from all potential predictors,
and their (predictive) validity was assessed with Harrell’s c
statistic (which varies from 0 to 1, indicating higher validity
when closer to 1). These models were further used to estimate
the corrected numerator of prevalence in multiple imputation as
implemented in Proc MI of SAS software (SAS Inst., Cary, NC). We
analyzed the resulting datasets (100 copies of the data, each withmissing values suitably imputed) with Proc MIANALYZE of SAS,
which incorporates the uncertainty caused by the imputation.
Denominators were the numbers of subjects eligible within the
regions of the survey.
Prevalence estimates and 95% conﬁdence intervals (95% CIs)
were ﬁnally corrected by the sensitivity error (sensitivity¼ 0.983)
of the screening questionnaire according to an equation previously
F. Guillemin et al. / Osteoarthritis and Cartilage 19 (2011) 1314e1322 1317developed for such survey design16. All analyses were stratiﬁed by
joint, age class and sex. A correlation of standardized prevalence
estimates with prevalence estimates of obesity by region17 was
sought using Spearman rank correlation coefﬁcient.
Standardized prevalence estimates were calculated according to
the European age and sex distribution for 2006 (Eurostat).
From pilot study results10, we estimated that a sample size of at
least 2500 (completers) in each considered age/sex strata was
needed to provide a precision of at least1.5% for prevalence of hip
and knee OA ranging between 2% and 17%. So, the estimated
number of completers needed was 20,000.
Results
During the study period, someone in 63,232 homes answered
a phone call, and 27,632 homes had at least one person between 40
and 75 years old. Among these people, 523 were screening refusers,
17,488 screened negative for presence of OA and 9621 screened
positive. Of these latter subjects, 1078 were early ascertainment
refusers (Fig. 1). A total of 3707 positive-screened subjects partici-
pated fully in the ascertainment phase, for 21,195 completers.
Reasons for nonparticipation included inability to contact to arrange
a visit to the clinic (514), refusal to participate in the ascertainment
visit (3389 late ascertainment refusers) and not showing up to the
scheduled visit (933 withdrawers). On scheduling the ascertain-
ment visit, 433 subjects reported nopain for severalmonths, 53 pain
with joint prosthesis, 46 inﬂammatory arthritis (rheumatoid
arthritis, spondylarthropathy) and 13 pain due to recent bone frac-
ture. These subjects were considered free of symptomatic OA.
Among the 3707 subjects who completed the whole ascertainment
phase, 2697 had non-symptomatic OA, 427 (11.5%) and 1066 (28.8%)
met the ACR clinical criteria for hip and knee OA respectively, andTable I
Participation and characteristics of subjects with a positive answer about OA on screenin
Completers Screening
refusers
Early
ascert
refuse
N¼ 21,195 N¼ 523 N¼ 10
N (%) N (%) N (%)
Sex
Male 7406 (34.9) 147 (28.1) 263 (2
Female 13,789 (65.1) 376 (71.9) 815 (7
Age
40e49 y 6856 (32.3) 84 (16.1) 168 (1
50e59 y 6600 (31.1) 145 (27.7) 311 (2
60e69 y 5144 (24.3) 141 (27.0) 368 (3
70e75 y 2595 (12.2) 153 (29.3) 231 (2
Screening questionnaire
Q1. Hip, groin or up thigh pain 1761 (8.3) e 456 (4
Q2. Hip pain in climbing up
stair or steep street
990 (4.7) e 276 (2
Q3. Hip mobility limitation 500 (2.4) e 111 (1
Q4. Hip OA 728 (3.4) e 186 (1
Q5. Knee pain 2341 (11.0) e 659 (6
Q6. Knee pain in stepping stairs
down or walking in steep street
1573 (7.4) e 425 (3
Q7. Knee swelling 465 (2.2) e 108 (1
Q8. Knee OA 1093 (5.2) e 282 (2
Region in France
Picardie (North) 3303 (15.6) 73 (14.0) 139 (1
Brittany (West) 3166 (14.9) 85 (16.3) 139 (1
Lorraine (East) 5381 (25.4) 146 (27.9) 271 (2
Côte d’Azur (South-East) 1497 (7.1) 32 (6.1) 110 (1
Paris area (North-Centre) 3391 (16.0) 84 (16.1) 199 (1
Toulouse area (South-West) 4457 (21.0) 103 (19.7) 220 (2
* Italicized ﬁgures in “all eligible” column represent the number (%) of interviewed su1010 had symptomatic and radiological OA, of which 317was hipOA
and 756 knee OA, affecting both joints in 63 subjects.
The participation rate differed according to region, age, sex and
socio-professional category, and missing data varied for the
different items of the screening questionnaire (Table I). Older
subjects were signiﬁcantly more likely to be refusers (all types),
whereas younger subjects had a higher probability of being
unreachable or withdrawing. Refusers were more frequently
women, and the frequency differed by region. Nonparticipants (all
types) more frequently gave a positive answer to the survey item
about pain, which indicated a not-at-random missingness process;
knee swelling was more frequent in early and late ascertainment
refusers; and self-reporting of knee or hip OAwasmore frequent for
late ascertainment refusers or withdrawers.
Imputation models were constructed for screening refusers
using documented variables found associated with OA in partici-
pants: age, sex and region (Harrell’s c¼ 0.72 for hip and 0. 71 for
knee); and for all other nonparticipants groups using age, region,
pain (Q1), mobility limitation (Q2) and self-reported diagnosis for
hip OA (Harrell’s c¼ 0.97) and age, sex, region, pain items (Q5, Q6)
and self-reported diagnosis for knee OA (Harrell’s c¼ 0.94).
Corrected estimates of prevalence and their 95% CIs by age
class for hip and knee symptomatic and radiological OA for
observed (completers) and imputed (eligible) subjects and
ascertained cases are in Appendix 3. Among 9172 eligible male
subjects, the prevalence of symptomatic and radiological hip OA
ranged from 0.9% to 3.9% for subjects aged 40e49 to 70e75
years old, and the prevalence of symptomatic and radiological
knee OA ranged from 2.1% to 10.1%. Among 18,460 eligible
female subjects, the prevalence of symptomatic and radiological
hip OA by age class ranged from 0.7% to 5.1% and that of
symptomatic and radiological knee OA from 1.6% to 14.9%g questionnaire*
ainment
rs
Secondarily
unreachable
Late
ascertainment
refusers
Withdrawals All eligible
78 N¼ 514 N¼ 3389 N¼ 933 N¼ 27,632
N (%) N (%) N (%) N (%)
4.4) 181 (35.2) 924 (27.3) 251 (26.9) 9172 (33.2)
5.6) 333 (64.8) 2465 (72.7) 682 (73.1) 18,460 (66.8)
5.6) 178 (34.6) 741 (21.9) 284 (30.4) 8311 (30.1)
8.8) 156 (30.4) 954 (28.1) 277 (29.7) 8443 (30.6)
4.1) 121 (23.5) 940 (27.7) 216 (23.2) 6930 (25.1)
1.4) 59 (11.5) 754 (22.2) 156 (16.7) 3948 (14.3)
2.3) 229 (44.6) 1510 (44.6) 454 (48.7) 4410 (16.3)
5.6) 135 (26.3) 901 (26.6) 272 (29.2) 2574 (9.5)
0.3) 61 (11.9) 387 (11.4) 127 (13.6) 1186 (4.4)
7.3) 72 (14.0) 591 (17.4) 187 (20.0) 1764 (6.5)
1.1) 314 (61.1) 2084 (61.5) 606 (65.0) 6004 (22.1)
9.4) 203 (39.5) 1355 (40.0) 437 (46.8) 3993 (14.7)
0.0) 57 (11.1) 360 (10.6) 129 (13.8) 1119 (4.1)
6.2) 114 (22.2) 930 (27.4) 252 (27.0) 2671 (9.9)
2.9) 56 (10.9) 630 (18.6) 17 (1.8) 4218 (15.3)
2.9) 24 (4.7) 410 (12.1) 76 (8.1) 3900 (14.1)
5.1) 40 (7.8) 578 (17.1) 302 (32.4) 6718 (24.3)
0.2) 29 (5.6) 283 (8.4) 110 (11.8) 2061 (7.5)
8.5) 207 (40.3) 627 (18.5) 290 (31.1) 4798 (17.4)
0.4) 158 (30.7) 861 (25.4) 138 (14.8) 5937 (21.5)
bjects with positive answers to each item.
Table II
Prevalence of hip symptomatic and radiological OA overall and by region
Eligible
subjects
All regions Picardie Brittany Lorraine Côte d’Azur Paris area Toulouse area
N % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Male
40e49 y 2920 0.96 0.28, 1.91 3.11 0.80, 6.54 0.47 0.00, 2.27 0.59 0.00, 2.14 0.29 0.00, 2.38 0.73 0.00, 2.78 0.63 0.00, 2.26
50e59 y 2811 1.58 0.59, 2.77 2.58 0.56, 4.57 1.49 0.58, 3.39 1.66 0.55, 3.57 1.83 0.55, 5.09 0.56 0.51, 3.59 1.56 0.52, 3.67
60e69 y 2303 3.17 1.58, 4.93 4.65 1.34, 6.89 4.18 1.30, 8.36 3.89 1.37, 6.51 1.19 1.33, 6.25 3.15 1.25, 6.35 1.61 1.29, 5.79
70e75 y 1138 3.90 1.39, 6.87 2.26 1.16, 8.66 5.63 1.12, 10.73 5.36 1.09, 10.27 2.04 1.06, 7.71 3.54 1.00, 8.52 3.29 1.01, 9.22
Female
40e49 y 5391 0.76 0.19, 1.45 1.00 0.01, 2.77 0.68 0.00, 2.33 0.97 0.20, 2.34 0.52 0.00, 2.38 0.68 0.00, 2.21 0.38 0.00, 1.41
50e59 y 5632 2.17 1.16, 3.23 2.92 0.68, 5.62 3.10 1.08, 6.08 2.58 0.93, 4.69 0.87 0.00, 3.59 1.27 0.00, 3.33 1.52 0.16, 3.44
60e69 y 4627 4.17 2.63, 5.76 4.98 1.87, 8.72 5.41 1.89, 9.80 5.05 2.20, 8.31 1.61 0.00, 4.80 3.47 0.26, 7.60 3.28 0.64, 6.50
70e75 y 2810 5.13 2.87, 7.50 6.59 1.95, 12.13 4.99 0.84, 10.11 5.78 1.37, 10.84 4.60 0.47, 11.08 4.43 0.30, 10.18 3.86 0.59, 8.29
F. Guillemin et al. / Osteoarthritis and Cartilage 19 (2011) 1314e13221318(Tables II, III and Fig. 2). Given the high sensitivity of the
screening questionnaire, these estimates corrected for sensi-
tivity error increased by 3.9% and 1.7% for knee and hip esti-
mates, respectively.
Hip and knee OA prevalence increased with age similarly for
both sexes and was higher for females >50 years old. Hip OA
prevalence was higher in the northern regions, namely, Pic-
ardie, Lorraine and Brittany, whereas knee OA was higher in the
northeastern regions, namely, Picardie and Lorraine, for males
and females, particularly for those with older age. Hip and knee
OA prevalence correlated with the prevalence of obesity by
region (rho¼ 0.92 and 0.54 respectively) (Table IV).
On standardization for theEuropeanpopulation40e75years old,
theprevalenceof hip andknee symptomatic and radiologicalOAwas
1.9% and 4.7% for men and 2.5% and 6.6% for women, respectively.
Discussion
This study of a representative population area in France gives
accurate national estimates of the prevalence of symptomatic hip
and knee OA in France. The age-related prevalence of symptomatic
hip OA of radiographic KeL 2 ranged from 0.9% to 3.9% and
0.7e5.1% for men and women, respectively, and that of symptom-
atic knee OA of KeL 2 from 2.1% to 10.1% and 1.6e14.9% for men
and women, respectively. The prevalence increased with age, was
higher among women >50 years old, and differed by geographical
region for both hip and knee OA.
This study has several strengths. First, it involved a large,
multiregional representative sample. The precision of the overall
estimates is high, and the sample size was large enough to obtain
multiregional estimates with reasonable precision. The scarcity ofTable III
Prevalence of knee symptomatic and radiological OA overall and by region
Eligible
subjects
All regions Picardie Brittany Lo
N % 95% CI % 95% CI % 95% CI %
Male
40e49 y 2920 2.09 0.93, 3.86 2.51 0.00, 6.21 1.20 0.00, 4.43 2
50e59 y 2811 4.72 2.99, 7.04 5.52 1.63, 10.73 2.28 0.47, 5.73 6
60e69 y 2303 6.80 4.53, 9.87 9.04 3.33, 15.90 4.79 0.62, 10.70 8
70e75 y 1138 10.14 6.31, 15.25 7.70 0.04, 16.70 4.78 0.00, 12.53 11
Female
40e49 y 5391 1.64 0.74, 2.59 2.04 0.40, 4.49 0.69 0.00, 2.42 2
50e59 y 5632 5.87 4.26, 7.50 6.96 3.78, 10.72 3.27 1.00, 6.24 8
60e69 y 4627 10.54 8.18, 12.91 12.59 7.34, 18.46 6.69 2.72, 11.49 14
70e75 y 2810 14.96 11.40, 18.51 17.18 9.92, 25.41 9.67 3.76, 16.31 19comparable data from other European countries limits drawing
any inferences from our observations. Second, the careful devel-
opment and validation of the OA screening questionnaire
contributed to the internal validity of our study; a similar initia-
tive was developed in Spain and published after the start of our
study8,18. The expense of the two-phase design is primarily in the
sensitivity error of the screening questionnaire, for which we
developed and applied a speciﬁc correction method16. The ques-
tionnaire is available and can be replicated in other countries. The
35% frequency of symptoms detected by this screening ques-
tionnaire was high as compared with other population-based
surveys3e8. Developed to maximize sensitivity of screening, the
instrument detects a low level of symptoms in subjects. Third, this
study involved both clinical and radiological criteria, which is
preferable to the use of only radiological criteria, because symp-
toms drive the need to seek care and for interventions. Clinical
ACR criteria or self-reported diagnosis alone seem to have inad-
equate sensitivity or speciﬁcity19,20 as compared with the clinical
exam for ascertainment. Such combination of clinical and radio-
logical criteria should be recommended for future prevalence
surveys.
Our study has some limitations. The participation rate was not
optimal but similar to that seen in previous studies with a similar
design8,21e23. A potential non-response bias, because of non-
respondents at the various steps of the two-phase procedure,
was unavoidable. This difﬁculty has been shown with surveys of
other musculoskeletal conditions24,25. Adjusting prevalence esti-
mates on various hypotheses (similarity of non-respondents,
maximum bias) does not help control such a selection bias. In
contrast, the recently developed multiple imputation techniques
we used in this study (contrary to previous ones) allow for usingrraine Côte d’Azur Paris area Toulouse area
95% CI % 95% CI % 95% CI % 95% CI
.78 0.87, 6.22 1.30 0.00, 7.37 1.31 0.00, 5.42 2.24 0.04, 5.60
.84 3.56, 11.79 3.23 0.00, 11.60 3.43 0.04, 8.69 4.30 1.14, 9.02
.11 3.76, 14.15 6.06 1.45, 15.99 4.34 0.82, 11.23 6.46 2.04, 12.99
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Fig. 2. Hip and knee symptomatic and radiological OA prevalence by age and sex.
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derivate estimates accounting for these corrections. These tech-
niques are particularly useful even when non-response occurs
not-at-random26, as was observed in our study. Notably, women
are overrepresented among the eligible subjects, probably because
they answered the phone more frequently than did men and did
not fully respect the subject selection by closest birthday date.
However, a response bias due to this phenomenon is unlikely or
minimal, because the subject selection occurred before we
mentioned that OA was the goal of the survey (health survey) and
asked screening questions. Second, the reliability of the reading of
radiographs, although tested in a pilot study, was not assessed in
the survey sample. Third, our estimates are not valid for an elderly
population living in institutions because we chose the upper
boundary of 75 years of age and household phone number.
Fourth, the cost of the survey was relatively high (up to 925 V perTable IV
Standardized hip and knee OA and obesity prevalence by region17
Region in France Knee OA (%) Hip OA (%) Obesity (%)
Picardie (North) 6.6 3.2 14.4
Brittany (West) 3.3 2.6 9.2
Lorraine (East) 7.5 2.6 13.1
Côte d’Azur (South-East) 3.9 1.2 7.7
Paris area (North-Centre) 5.3 1.7 8.1
Toulouse area (South-West) 5.2 1.6 8.8
Spearman rho* 0.54 0.92
* Spearman correlation coefﬁcient of joint OA with obesity prevalence.conﬁrmed case), given the strategy used to identify cases from
population-based screening.
Our prevalence estimates are lower than others. Several expla-
nations are possible. First, our cases of symptomatic OA relied on
self-reported symptoms or diagnosis and on radiographic evidence
checked by a rheumatologist. Many subjects seen by rheumatologists
had self-reported symptoms or met clinical ACR criteria for OA, or
had referred pain. These cases could have been classiﬁed as OA in
other studies by self-reported symptoms alone or by a combination
of self-reported symptoms and radiography results. The conse-
quences of the disease for public health (i.e., access to care, impact on
daily life of this chronic condition), as well as clinically (i.e., health
care use, development of new treatments to alleviate symptoms and
disease progression) are major justiﬁcations to focus on symptom-
atic OA. Second, the timeframe of the question about pain or
symptoms probably affects prevalence estimates. The NHANES III
study recorded lifetime history of knee pain with a 6-week duration
and the estimates for knee OA were 10.0% and 13.6% for men and
women respectively. The Framingham Study recorded lifetime
prevalence of knee pain of 1-month duration, and found estimates
of 6.2% in men and 7.6% in women. Other studies have used
“current knee pain on most days,” as in the Johnston County OA
project where prevalence estimates were 13.5% and 18.7% for men
and women knee OA respectively and 8.3% and 11.1% for hip OA. In
our study, we recorded symptoms occurring during the previous 4
weeks. This time period may have lowered the prevalence by
excluding data on intermittent symptoms becoming asymptom-
atic between the screening and ascertainment phases.
Previous prevalence estimates differ by population and
methods used (Appendix 1). In surveys with screening question-
naires, the estimates vary greatly depending on the questions
used to elicit symptom information. Radiography protocols differ
between studies. We obtained weight-bearing AP, weight-bearing
posteroanterior semiﬂexed and axial views for knees and an AP
view of the pelvis and oblique view for the hip. Such complete
radiography assessment can potentially classify more subjects as
having OA27. Very few studies are directly comparable to ours
because published prevalence estimates are rarely provided in
a similar format by sex and age class, thus preventing us from
calculating standardized prevalence estimates for direct compar-
ison. Our population sample included subjects up to 75 years old,
whereas other studies did not. The prevalence of OA increased
with age for both sexes and was greater for women thanmen from
age 50 years, as was found in numerous other studies28. Over time,
raw estimates from studies of previous decades have probably
increased with the aging of the population and increase in obesity,
a known and increasingly frequent risk factor for OA. The preva-
lence of obesity and ethnic minorities showing differential risk for
OA differ between industrialized countries in Europe and the
United States. The prevalence of symptomatic OA (clinical criteria)
in European countries is estimated to range from 5.4% to 29.8%
and 0.9e9.7% for knee and hip OA, respectively. Our results show
geographic heterogeneity with a decreasing northesouth
gradient for hip OA and a decreasing north-east to south-western
gradient for knee OA. Interestingly, a similar and correlated
distribution of the prevalence of obesity was consistently reported
over the past decades in regions in France we investigated17. This
ecological observation gives some additional validity to our esti-
mate of regional heterogeneity. Compared to other European
studies, our multiregional observations are similar, for a higher
prevalence reported in northern countries, although we used
different methods and OA deﬁnitions. The ﬁndings are similar to
those for knee OA but lower than those for hip OA reported from
Spain8. Of note, inﬂammatory rheumatic diseases show a similar
direction gradient in prevalence in France29 and in Europe1. Most
F. Guillemin et al. / Osteoarthritis and Cartilage 19 (2011) 1314e13221320of the other estimates are from smaller, nonrepresentative studies
or from studies involving only self-reported symptoms without
radiographic ascertainment.
The frequency of rheumatic diseases is expected to double
between 1991 and 203330, and OA is the most frequent of these.
As a consequence, functional impairment, dependence and cost
will increase. Prevalence estimates give a picture of the distri-
bution of the disease in the population. Accurate estimates of OA
prevalence are critical for understanding the age and sex distri-
bution of the disease, identifying high-risk groups and guiding
intervention efforts efﬁciently to limit the progression of the
disease. This study updates previous estimates, which is partic-
ularly important because only a few studies were conducted in
the past 10 years, even though the epidemiology of risk factors for
OA is changing with an increase in mean body mass index and the
aging of the population. These results are important for public
health to assess future needs, determine the burden of disease,
investigate modiﬁable risk factors and develop focused inter-
ventions to prevent, treat and slow the progression of OA, in other
words, help decision-makers forecast future needs at the national
and European level. The survey also provides a unique opportu-
nity to recruit a large and representative sample of patients with
lower-limb symptomatic OA in a cohort study.Conclusions
We conducted a two-phase population-based survey to provide
prevalence estimates of symptomatic hip and knee OA in France.
Our study increases knowledge about population-based prevalence
estimates of this condition in Europe. Our estimates suggest that
the prevalence of symptomatic hip and knee OA increases by age for
both sexes and is higher for women older than 50 years in France.
The geographical distribution of hip and knee OA parallels the
distribution of obesity over the investigated area.Appendix 1
Prevalence of symptomatic knee and hip OA by OA deﬁnition
Studyreference Period Age class O
Knee
France Present study 2007e2009 40e75 y S
Spain Quintana8 2002e2003 60e90 y S
China Zhang31 1998e2000 60 y S
Japan Muraki32 2005 60 y C
USA Framingham3 1983e1985 63e70 y S
Johnston County OA project6 1991e1997 45 y S
NHANES III4 1991e1994 60 y S
Italy Salafﬁ33 2004 18 y A
Mannoni34 2003 65 y A
Greece Andrianakos35 1996e1999 19 y A
Norway Grotle36 2004 24e76 y S
Netherlands Picavet37 1998 25 y S
Hip
France Present study 2007e2009 40e75 y S
Spain Quintana8 2002e2003 60e90 y S
China Nevitt38 1998e2000 60 y S
USA Johnston County OA project5 1991e1997 45 y S
Italy Salafﬁ33 2004 18 y A
Mannoni34 2003 65 y A
Greece Andrianakos35 1996e1999 19 y A
Norway Grotle36 2004 24e76 y S
NL Picavet37 1998 25 y S
* Indicates standardized prevalence using European Union population (Eurostat).Author contributions
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Total Women Men
creening then clinical exam and radiographs e 6.6* 4.7*
creening then clinical exam and radiographs 12.2 14.9 8.7
creening then clinical exam and radiographs e 15.0 5.6
linical exam and radiographs 26.1 31.8 15.8
elf-reported symptoms and radiographs 7.0 7.6 6.2
elf-reported symptoms and radiographs 16.4* 18.7* 13.5*
elf-reported symptoms and radiographs 12.1* 13.6* 10.0*
CR clinical criteria 5.4 e e
CR clinical criteria 29.8 e e
CR clinical criteria 6.0 8.6 3.2
elf-reported diagnosis 7.1 7.9 6.2
elf-reported diagnosis e 13.6* 10.1*
creening then clinical exam and radiographs e 2.5* 1.9*
creening then clinical exam and radiographs 7.4 8.0 6.7
creening then clinical exam and radiographs e 0.1 0.0
elf-reported symptoms and radiographs 9.7* 11.1* 8.3*
CR clinical criteria 1.6 e e
CR clinical criteria 7.7 e e
CR clinical criteria 0.9 1.5 0.3
elf-reported diagnosis 5.5 6.2 4.6
elf-reported diagnosis e 9.6* 3.9*
Appendix 3
Prevalence estimates in completers (observed) and noncompleters (imputed) by age class, corrected for sensitivity error of the screening questionnaire
40e49 y 50e59 y 60e69 y 70e75 y
N % 95% CI N % 95% CI N % 95% CI N % 95% CI
Hip male
Completers 2413 0.67 0.34, 1.00 2295 1.11 0.66, 1.51 1855 2.36 1.63, 3.00 843 2.53 1.44, 3.55
Screening refusers 28 0.62 0.00, 4.85 43 1.23 0.00, 6.08 42 2.96 0.00, 10.28 34 2.90 0.00, 10.53
Early ascertainment refusers 52 2.39 0.00, 8.74 82 3.09 0.00, 8.17 87 5.43 0.00, 11.96 42 7.53 0.00, 18.52
Unreached subjects 71 2.55 0.00, 7.65 55 3.98 0.00, 11.17 40 5.39 0.00, 15.00 15 9.56 0.00, 30.78
Late ascertainment refusers 263 2.34 0.00, 5.15 262 4.17 0.51, 7.84 228 7.28 2.66, 11.91 171 7.81 2.17, 13.44
Withdrawals 93 2.58 0.00, 6.99 74 3.85 0.00, 9.63 51 8.74 0.00, 19.33 33 12.46 0.00, 28.19
Eligible subjects 2920 0.96 0.28, 1.91 2811 1.58 0.59, 2.77 2303 3.17 1.58, 4.93 1138 3.90 1.39, 6.87
Hip female
Completers 4443 0.39 0.20, 0.57 4305 1.44 1.08, 1.80 3289 2.66 2.10, 3.22 1752 2.79 2.01, 3.57
Screening refusers 56 0.56 0.00, 3.30 102 1.41 0.00, 4.42 99 2.80 0.00, 7.42 119 2.46 0.00, 6.45
Early ascertainment refusers 116 2.31 0.00, 6.23 229 4.24 0.43, 8.06 281 8.13 3.60, 12.66 189 8.32 2.27, 14.36
Unreached subjects 107 2.64 0.00, 7.12 101 4.14 0.00, 9.47 81 7.49 0.00, 15.55 44 9.04 0.00, 20.70
Late ascertainment refusers 478 2.40 0.20, 4.66 692 4.90 2.37, 7.44 712 8.17 5.33, 11.02 583 10.67 6.73, 14.62
Withdrawals 191 3.35 0.00, 7.09 203 5.35 0.73, 9.97 165 9.48 2.86, 16.11 123 8.56 1.60, 15.52
Eligible subjects 5391 0.76 0.19, 1.45 5632 2.17 1.16, 3.23 4627 4.17 2.63, 5.76 2810 5.13 2.87, 7.50
Knee male
Completers 2413 1.08 0.66, 1.50 2295 3.26 2.51, 4.01 1855 4.82 3.81, 5.83 843 5.92 4.28, 7.56
Screening refusers 28 1.40 0.00, 7.83 43 2.76 0.00, 9.48 42 5.02 0.00, 15.38 34 6.82 0.00, 19.05
Early ascertainment refusers 52 7.38 0.00, 16.63 82 12.56 2.66, 22.46 87 16.41 6.22, 26.61 42 37.17 16.68, 57.66
Unreached subjects 71 12.33 1.91, 22.74 55 15.12 2.44, 27.79 40 17.75 1.34, 34.15 15 20.30 0.00, 46.53
Late ascertainment refusers 263 8.08 3.54, 12.62 262 13.23 7.46, 18.99 228 17.18 10.12, 24.24 171 25.15 15.93, 34.38
Withdrawals 93 9.16 0.84, 17.49 74 14.57 4.51, 24.62 51 24.72 8.87, 40.57 33 22.46 4.50, 40.41
Eligible subjects 2920 2.09 0.93, 3.86 2811 4.72 2.99, 7.04 2303 6.80 4.53, 9.87 1138 10.14 6.31, 15.25
Knee female
Completers 4443 0.84 0.57, 1.12 4305 3.74 3.15, 4.33 3289 6.23 5.36, 7.09 1752 8.13 6.79, 9.46
Screening refusers 56 1.41 0.00, 6.03 102 3.41 0.00, 8.64 99 6.26 0.00, 13.15 109 7.85 0.86, 14.84
Early ascertainment refusers 116 6.22 0.47, 11.97 229 11.72 5.85, 17.60 281 19.82 13.38, 26.26 189 25.40 17.03, 33.76
Unreached subjects 107 5.04 0.00, 10.69 101 11.49 3.37, 19.62 81 20.89 9.02, 32.76 44 27.64 10.50, 44.78
Late ascertainment refusers 478 5.03 2.20, 7.85 692 13.92 10.12, 17.72 712 22.72 18.35, 27.08 583 28.24 22.89, 33.59
Withdrawals 191 7.13 1.91, 12.36 203 15.30 8.71, 21.90 165 25.57 16.13, 35.02 123 35.04 23.66, 46.42
Eligible subjects 5391 1.64 0.74, 2.59 5632 5.87 4.26, 7.50 4627 10.54 8.18, 12.91 2800 14.96 11.40, 18.51
Appendix 2
Screening questionnaire for symptomatic hip and knee OA9
Concerning the hip
Q1. During the last 4 weeks, have you had pain in the hip, groin, or in the upper thigh?
Q2. Do you have pain in the hip, groin, or in the upper thigh while climbing stairs or walking down slopes?
Q3. Do you have a limitation in the range of motion of one or both hips?
Q4. Do you have hip OA?
Concerning the knee
Q5. During the last 4 weeks, have you had knee pain?
Q6. Do you have knee pain while climbing stairs or walking down slopes?
Q7. During the last 4 weeks, have you had swelling in one or both knees?
Q8. Do you have knee OA?
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Supplementary data related to this article can be found online at
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References
1. Silman AJ, Hochberg M. Epidemiology of the Rheumatic
Diseases. Oxford University Press; 2001.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H,
Deyo RA, et al. Estimates of the prevalence of arthritis and
other rheumatic conditions in the United States. Part II.
Arthritis Rheum 2008;58:26e35.3. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W,
Meenan RF. The prevalence of knee osteoarthritis in the
elderly. The Framingham Osteoarthritis Study. Arthritis Rheum
1987;30:914e8.
4. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee oste-
oarthritis in the United States: arthritis data from the Third
National Health and Nutrition Examination Survey 1991e94.
J Rheumatol 2006;33:2271e9.
5. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD,
Woodard J, et al. Prevalence of hip symptoms and radiographic
and symptomatic hip osteoarthritis in African Americans and
Caucasians: the Johnston County Osteoarthritis Project.
J Rheumatol 2009;36:809e15.
F. Guillemin et al. / Osteoarthritis and Cartilage 19 (2011) 1314e132213226. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD,
Woodard J, et al. Prevalence of knee symptoms and radio-
graphic and symptomatic knee osteoarthritis in African
Americans and Caucasians: the Johnston County Osteoarthritis
Project. J Rheumatol 2007;34:172e80.
7. van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP,
Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer
survey. Comparison of radiological osteoarthritis in a Dutch
population with that in 10 other populations. Ann Rheum Dis
1989;48:271e80.
8. Quintana JM, Arostegui I, Escobar A, Azkarate J, Goenaga JI,
Lafuente I. Prevalence of knee and hip osteoarthritis and the
appropriateness of joint replacement in an older population.
Arch Intern Med 2008;168:1576e84.
9. Morvan J, Roux CH, Fautrel B, Rat AC, Euller-Ziegler L,
Loeuille D, et al. A caseecontrol study to assess sensitivity and
speciﬁcity of a questionnaire for the detection of hip and knee
osteoarthritis. Arthritis Rheum 2009;61:92e9.
10. Roux CH, Saraux A, Mazieres B, Pouchot J, Morvan J, Fautrel B,
et al. Screening for hip and knee osteoarthritis in the general
population: predictive value of a questionnaire and prevalence
estimates. Ann Rheum Dis 2008;67:1406e11.
11. Salmon CT, Nichols JS. The next-birthday method of respon-
dent selection. Public Opin Q 1983;47:270e6.
12. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al.
Development of criteria for the classiﬁcation and reporting of
osteoarthritis. Classiﬁcation of osteoarthritis of the knee. Diag-
nostic and Therapeutic Criteria Committee of the American
Rheumatism Association. Arthritis Rheum 1986;29:1039e49.
13. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D,
Brandt K, et al. The American College of Rheumatology criteria
for the classiﬁcation and reporting of osteoarthritis of the hip.
Arthritis Rheum 1991;34:505e14.
14. Kellgren JH, Lawrence JS. Radiological assessment of osteo-
arthrosis. Ann Rheum Dis 1957;16:494e502.
15. Rubin D. Multiple Imputation for Nonresponse in Surveys.
New York: John Wiley and Sons; 1987.
16. Morvan J, Coste J, RouxCH, Euller-Ziegler L, SarauxA,Guillemin F.
Prevalence in two-phase surveys: accuracy of screening proce-
dure and corrected estimates. Ann Epidemiol 2008;18:261e9.
17. de Saint PT. Evolution of obesity by social status in France,
1981e2003. Econ Hum Biol 2009;7:398e404.
18. Quintana JM, Arostegui I, Escobar A, Lafuente I, Arenaza JC,
Garcia I, et al. Validation of a screening questionnaire for hip
and knee osteoarthritis in old people. BMC Musculoskelet
Disord 2007;8:84.
19. LaValley M, McAlindon TE, Evans S, Chaisson CE, Felson DT.
Problems in the development and validation of questionnaire-
based screening instruments for ascertaining cases with
symptomatic knee osteoarthritis: the Framingham Study.
Arthritis Rheum 2001;44:1105e13.
20. Peat G, Thomas E, Duncan R, Wood L, Hay E, Croft P. Clinical
classiﬁcation criteria for knee osteoarthritis: performance in
the general population and primary care. Ann Rheum Dis
2006;65:1363e7.
21. Kmetic A, Joseph L, Berger C, Tenenhouse A. Multiple impu-
tation to account for missing data in a survey: estimating the
prevalence of osteoporosis. Epidemiology 2002;13:437e44.
22. Peat G, Thomas E, Handy J, Wood L, Dziedzic K, Myers H, et al.
The Knee Clinical Assessment Study e CAS(K). A prospective
study of knee pain and knee osteoarthritis in the general
population: baseline recruitment and retention at 18 months.
BMC Musculoskelet Disord 2006;7:30.23. Lohmander LS, Gerhardsson de Verdier M, Rollof J, Nilsson PM,
Engstrom G. Incidence of severe knee and hip osteoarthritis in
relation to different measures of body mass: a pop-
ulation-based prospective cohort study. Ann Rheum Dis
2009;68:490e6.
24. Urwin M, Symmons D, Allison T, Brammah T, Busby H,
Roxby M, et al. Estimating the burden of musculoskeletal
disorders in the community: the comparative prevalence of
symptoms at different anatomical sites, and the relation to
social deprivation. Ann Rheum Dis 1998;57:649e55.
25. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren’s syndrome:
a community-based study of prevalence and impact. Br J
Rheumatol 1998;37:1069e76.
26. Sterne JA, White IR, Carlin JB, Spratt M, Royston P,
Kenward MG, et al. Multiple imputation for missing data in
epidemiological and clinical research: potential and pitfalls.
BMJ 2009;338:b2393.
27. Duncan RC, Hay EM, Saklatvala J, Croft PR. Prevalence of
radiographic osteoarthritis e it all depends on your point of
view. Rheumatology (Oxford) 2006;45:757e60.
28. Anderson JJ, Felson DT. Factors associated with osteoarthritis
of the knee in the ﬁrst national Health and Nutrition Exami-
nation Survey (HANES I). Evidence for an association with
overweight, race, and physical demands of work. Am J Epi-
demiol 1988;128:179e89.
29. Roux CH, Saraux A, Le Bihan E, Fardellone P, Guggenbuhl P,
Fautrel B, et al. Rheumatoid arthritis and spondyloar-
thropathies: geographical variations in prevalence in France.
J Rheumatol 2007;34:117e22.
30. Badley EM, Wang PP. Arthritis and the aging population:
projections of arthritis prevalence in Canada 1991 to 2031.
J Rheumatol 1998;25:138e44.
31. Zhang Y, Xu L, Nevitt MC, Aliabadi P, Yu W, Qin M, et al.
Comparison of the prevalence of knee osteoarthritis between
the elderly Chinese population in Beijing and whites in the
United States: The Beijing osteoarthritis study. Arthritis
Rheum 2001;44:2065e71.
32. Muraki S, Oka H, Akune T, Mabuchi A, En-yo Y, Yoshida M,
et al. Prevalence of radiographic knee osteoarthritis and its
association with knee pain in the elderly of Japanese
population-based cohorts: the ROAD study. Osteoarthritis
Cartilage 2009;17:1137e43.
33. Salafﬁ F, De Angelis R, Grassi W. Prevalence of musculoskeletal
conditions in an Italian population sample: results of
a regional community-based study. I. The MAPPING study. Clin
Exp Rheumatol 2005;23:819e28.
34. Mannoni A, Briganti MP, Di Bari M, Ferrucci L, Costanzo S,
Serni U, et al. Epidemiological proﬁle of symptomatic osteo-
arthritis in older adults: a population based study in Dico-
mano, Italy. Ann Rheum Dis 2003;62:576e8.
35. Andrianakos AA, Kontelis LK, Karamitsos DG, Aslanidis SI,
Georgountzos AI, Kaziolas GO, et al. Prevalence of symptomatic
knee, hand, and hip osteoarthritis in Greece. The ESORDIG
study. J Rheumatol 2006;33:2507e13.
36. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Prevalence
and burden of osteoarthritis: results from a population survey
in Norway. J Rheumatol 2008;35:677e84.
37. Picavet HS, Hazes JM. Prevalence of self reported musculo-
skeletal diseases is high. Ann Rheum Dis 2003;62:644e50.
38. Nevitt MC, Xu L, Zhang Y, Lui LY, Yu W, Lane NE, et al. Very low
prevalence of hip osteoarthritis among Chinese elderly in
Beijing, China, compared with whites in the United States: the
Beijing osteoarthritis study. Arthritis Rheum 2002;46:1773e9.
